Worth reading
47Recurring
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
12200
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of stock acquisition rights as stock-based compensation stock options
Who receives how much
12,200 shares of the Company’s common stock (122 stock acquisition rights, representing 100 shares per right)
4 directors, consisting of 122 stock acquisition rights representing 12,200 underlying shares
The lower thin line represents the existing number of shares to which these shares will be added.
The accounting fair value as of the allocation date. No cash payment is required in exchange for the stock acquisition rights.
Amount of funds to be raised
Total amount to be paid: No cash payment is required. Estimated net proceeds: Not disclosed
Total Stock-Based Compensation
Director compensation equivalent to the fair accounting value on the allotment date. Amount: not disclosed
Terms of the stock acquisition rights
Exercise price
The initial exercise price is ¥1 per share. Adjustment provisions apply in the event of a share split or reverse share split. The lower limit for revisions is Not disclosed.
Exercise period
Start Date 10 June 2026 / End date 9 June 2041
Number of Stock Acquisition Rights
Total issued: 122 stock acquisition rights. Number of outstanding unexercised rights: Not disclosed
Reason for acquisition without consideration
After the exercise period expires, or, even during the exercise period, 5 years after the later of the date on which the director or senior executive officer retires. This also applies in the event of a serious violation of laws or internal rules, a sentence of imprisonment or more severe punishment, appointment to a competing company without the Company’s prior approval, the death of a successor to the rights, an offer to waive all rights, or a resolution by the Board of Directors to acquire all or part of the rights.
Conditions on transfer restrictions
Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.
Transfer restriction period
The duration is Not disclosed. The holders of the stock acquisition rights and their successors may not transfer the rights or provide them as collateral.
Categories and Number of Persons Covered
4 directors, consisting of 122 stock acquisition rights representing 12,200 underlying shares
Intended allottee's holding policy
The holders of the stock acquisition rights and their successors may not transfer the stock acquisition rights or pledge them as collateral.
Payment date
Not applicable (no cash payment is required in exchange for the stock acquisition rights)
Basis for determining the amount to be paid
The issue price of the stock acquisition rights is the accounting fair value as of the allocation date. The periods used for the reference closing price and average share price, and the discount and premium rates, are Not disclosed.
Most recent equity financing
21 May 2025: Issuance of stock acquisition rights as stock compensation-type stock options, approved for up to 19,400 shares
Impact on Business Performance
The purpose is to strengthen the linkage with performance and the share price and to motivate and encourage sustained improvement in performance over the medium to long term and an increase in corporate value. The monetary impact on performance is Not disclosed.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of stock acquisition rights as stock-based compensation stock options |
| Number of shares to be issued or disposed of | 12,200 shares of the Company’s common stock (122 stock acquisition rights, representing 100 shares per right) |
| Issue price and disposal price | The accounting fair value as of the allocation date. No cash payment is required in exchange for the stock acquisition rights. |
| Amount of funds to be raised | Total amount to be paid: No cash payment is required. Estimated net proceeds: Not disclosed |
| Payment date | Not applicable (no cash payment is required in exchange for the stock acquisition rights) |
| Intended allottee | 4 directors, consisting of 122 stock acquisition rights representing 12,200 underlying shares |
| Intended allottee's holding policy | The holders of the stock acquisition rights and their successors may not transfer the stock acquisition rights or pledge them as collateral. |
| Basis for determining the amount to be paid | The issue price of the stock acquisition rights is the accounting fair value as of the allocation date. The periods used for the reference closing price and average share price, and the discount and premium rates, are Not disclosed. |
| Exercise price | The initial exercise price is ¥1 per share. Adjustment provisions apply in the event of a share split or reverse share split. The lower limit for revisions is Not disclosed. |
| Exercise period | Start Date 10 June 2026 / End date 9 June 2041 |
| Number of Stock Acquisition Rights | Total issued: 122 stock acquisition rights. Number of outstanding unexercised rights: Not disclosed |
| Transfer restriction period | The duration is Not disclosed. The holders of the stock acquisition rights and their successors may not transfer the rights or provide them as collateral. |
| Reason for acquisition without consideration | After the exercise period expires, or, even during the exercise period, 5 years after the later of the date on which the director or senior executive officer retires. This also applies in the event of a serious violation of laws or internal rules, a sentence of imprisonment or more severe punishment, appointment to a competing company without the Company’s prior approval, the death of a successor to the rights, an offer to waive all rights, or a resolution by the Board of Directors to acquire all or part of the rights. |
| Categories and Number of Persons Covered | 4 directors, consisting of 122 stock acquisition rights representing 12,200 underlying shares |
| Total Stock-Based Compensation | Director compensation equivalent to the fair accounting value on the allotment date. Amount: not disclosed |
| Most recent equity financing | 21 May 2025: Issuance of stock acquisition rights as stock compensation-type stock options, approved for up to 19,400 shares |
| Impact on Business Performance | The purpose is to strengthen the linkage with performance and the share price and to motivate and encourage sustained improvement in performance over the medium to long term and an increase in corporate value. The monetary impact on performance is Not disclosed. |
Items this document does not state (11)
Total issue valueEstimated issuance expensesSpecific use of fundsDilution RateTotal number of issued sharesConditions for lifting transfer restrictionsUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the linkage between directors’ compensation and the Company’s performance and share price, and to motivate and encourage directors to improve performance over the medium to long term and increase corporate value by sharing with shareholders not only the benefits of a rising share price but also the risks of a decline.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.